Comparable endpoint decisions in accelerated approval: a public docket and a duty to reconcile
Likely Human
Background. The Food and Drug Administration grants accelerated approval on surrogate and intermediate clinical endpoints judged reasonably likely to predict clinical benefit. Its December 2024 draft guidance names the dimensions of that judgment, then states that the evidence satisfy...
The Verdict
ClassificationLikely Human
ConfidenceMedium confidence
Community Verdict
Sign in to vote
Be the first to vote on this assessment.
Embed Badge
Add this badge to your site to show the AI classification for this content.
[](https://real.press/content/968916f1-6a8c-489d-a108-8ef4632ffcb0)